What is Ductal Carcinoma in Situ (DCIS)?
DCIS is found in the cells that line the ducts in one or both breasts. DCIS is considered the earliest form of breast cancer and is sometimes referred to as Stage 0 (zero) or non-invasive cancer.1 Whilst DCIS is pre-invasive or pre-cancerous, a positive diagnosis with DCIS can mean your doctor will recommend a treatment plan with the aim of preventing potential invasive cancer.1
Understand the best treatment options for your DCIS
GenesisCare has access to risk assessment-based test which may help determine the potential risk of ductal carcinoma in situ (DCIS) recurring after surgery.2 The assessment also looks at the potential risk of progression to invasive breast cancer, and the possible impact of radiation therapy (RT) in reducing the risk.2
Whilst DCIS itself is may not always be considered life threatening, there is some evidence suggesting that patients with DCIS might have an increased risk of death from breast cancer compared with those without DCIS.1-4 There are several proposed reasons for this, including variations in treatment practice due to geographical access and potentially differing clinical protocols.3,4
The risk assessment-based test that GenesisCare has access to may potentially help doctors and patients when selecting a treatment based on the biology of a particular tumour type, alongside clinical pathology.2 It was developed with the aim of assisting both patients and clinicians when they are making treatment decisions.2
There are no additional procedures required to complete testing, as it can be performed on existing tissue from a biopsy or breast surgery.2
For more information ask your doctor or contact us directly
Email: DCISIONRT@genesiscare.com
- The risk assessment-based test might help assess the risk of DCIS coming back (recurring) and/or spreading,
- It might also help predict whether radiation therapy will benefit a patient,
- If testing is accessed through GenesisCare there is no additional cost - If no radiation therapy is needed at the time of results, there will be no cost to patients for the test.
Further testing might help DCIS patients as a decision aid too.2 The aim is to help assess the risk of recurrence or of developing invasive disease.5 The outcome of the test result might help when considering suitable treatment options.2
You can find out more by either having your doctor contact us and we can explain the testing to them. They can then determine whether testing is suitable for your case. Alternatively, you can contact us and one of our clinical interest staff can speak to you.
The additional information provided by testing might help you and your doctor understand the potential risk of DCIS recurring.2 It also might help your doctor as part of their treatment decisions and algorithms.2
Doctors can arrange testing for their patients with DCIS. The test can be applied to the breast tissue sample taken as part of a biopsy or breast surgery; no additional procedure is required.2
The test was recently launched in Australia but is not supported through the Medicare Benefits Scheme or listed on the Therapeutic Goods Association. All tissue sample(s) used for analysis are sent offshore to California in the USA for processing.
The test has been validated in published studies with over 3,500 DCIS patients worldwide.5-9 The test is supported by Level 1b clinical evidence.1
Results will be shared with the doctor and a radiation oncologist within approximately three weeks. A follow-up appointment may then be arranged with the doctor to discuss results and what those may mean for a patient’s treatment plan.
Click here to find out more about the treatment journey for breast cancer and risk assessment based testing at GenesisCare.
Find a centre near you
Disclaimer
This information is provided for the sole purpose of disseminating educational information in relation to DCIS and DCISionRT. The content is not intended to provide medical advice or treatment recommendations and should not be relied on as such. The information does not take the place of professional or medical advice. While GenesisCare makes every effort to ensure the accuracy of the content, GenesisCare does not guarantee its accuracy, currency or completeness and does not accept any responsibility or liability for any injury, loss or damage incurred by use of or reliance on the content. Before relying on the content, you should carefully evaluate it and use your own professional discretion when determining its appropriateness for assessing the clinical needs of your patients (including considering any risks relevant to individual patients in the context of their full treatment protocol). The content includes information from third parties. This information is provided for convenience only and does not necessarily reflect the views of GenesisCare or signify that GenesisCare endorses such information.
- Shah C, et al. Ann Surg Oncol. 2021; 28:5974–84
- National Comprehensive Cancer Network. NCCN Guidelines; Ducted Carcinoma In Situ Breast Cancer (DCIS) Version 4.2023, Last updated March 2023, [cited Apr. 2023]. Available from: https://www.nccn.org
- https://www.aihw.gov.au/getmedia/e414a344-ab3d-4a35-a79b-a29723f22939/aihw-can-135.pdf
- van Seijen M, et al. Br J Cancer 2019; 13;121(4):285–292
- https://preludedx.com/dcisionrt/
- Weinmann S, et al. Clin Cancer Res 2020; (26)(15):4054-4063
- Bremer TM, et al. Clin Cancer Res 2018; 1;24(23):5895-5901.
- Warnberg F, et al. Cancer Res 2018; 78 (4 Suppl);GS5-08.
- PreludeDX 2016-2017. Data on file